Viral RNA Synthesis Inhibition

Viral RNA synthesis inhibition refers to the process of blocking the replication and transcription of viral RNA genomes within infected host cells. This is a critical antiviral strategy, as many viruses—especially RNA viruses—rely on specialized enzymes (such as viral RNA-dependent RNA polymerases, or RdRps) and unique membrane-associated replication complexes to synthesize their genetic material. Inhibiting these processes can effectively halt virus propagation. The primary molecular targets for this mechanism are viral RdRp, membrane-bound replicase complexes, and other non-structural proteins involved in viral genome synthesis. Common mechanisms of inhibition include nucleoside/nucleotide analog incorporation, disruption of membrane-bound steps, and protein-protein interaction inhibition. Targeting viral RNA synthesis has led to several broad-spectrum antivirals, such as Remdesivir and Molnupiravir. Because human cells lack RdRps used by most pathogenic viruses—and because some steps like DMV formation are unique—the risk of off-target toxicity is reduced compared with other antiviral strategies. However, high specificity remains crucial since nucleotide analogs could potentially affect cellular nucleic acid metabolism if not selective enough.

Inhibition of viral RNA-dependent RNA polymerase (RdRp) through nucleoside/nucleotide analog incorporation leading to chain termination or mutagenesis; disruption of membrane-bound replicase complex formation or function.